Women produce testosterone. The ovaries and the adrenal glands make it across adult life, and it circulates at roughly a tenth to a twentieth of male concentrations. It is a normal female hormone, not a borrowed male one.
The difficulty is the distance between what testosterone replacement therapy for women is proven to do and what it is marketed to do. One indication carries international society backing. The longer list on a typical clinic page does not, and the dose is where the real risk sits.
The Verdict
How testosterone works in a woman's body
Female testosterone comes from two places: the ovaries, and the adrenal glands by way of precursors such as DHEA. Some of it also converts to estradiol in fat and other tissues, so the two hormones are linked rather than separate systems.
The decline pattern is the part most people get wrong. Testosterone falls gradually from the twenties onward, so a woman in her forties typically sits well below her early-twenties level. It does not drop at menopause the way estrogen does. Menopause is an ovarian estrogen event, and the post-menopausal ovary continues to produce androgens.
That is why "menopause causes low testosterone" is a weak claim, and why a low reading in a 45-year-old is usually age rather than a new deficiency. The three stages of menopause sets out what actually changes at each point.
What the evidence supports, and what it does not
A global consensus position statement on testosterone therapy for women, endorsed by bodies including the International Menopause Society, the Endocrine Society and The Menopause Society, reached one conclusion on indications: the only evidence-based use is hypoactive sexual desire disorder in post-menopausal women. That means low sexual desire that causes the woman personal distress, after other contributors have been addressed.
Everything else is unproven rather than disproven, which is a meaningful difference and still a poor reason to prescribe. Ordered by strength of evidence, strongest first.
| Claim | What the evidence supports | What to do instead or as well |
|---|---|---|
| Low sexual desire with distress after menopause | Strongest. This is the one indication covered by an international consensus position | Reasonable to trial with a prescriber, at a female dose, with levels checked |
| Arousal, orgasm and sexual pleasure in those same women | Supported as part of the same effect on sexual function | Usually moves together with desire rather than separately |
| Energy and fatigue | Not established as an indication | Thyroid, ferritin, sleep apnoea and mood explain far more fatigue than testosterone does |
| Mood and general wellbeing | Not established as an indication | Depression and anxiety need their own assessment and treatment |
| Memory, focus and cognition | Not established as an indication | No trial basis for prescribing testosterone to protect cognition |
| Muscle mass and strength | Not established at female physiological doses | The muscle effects people have read about come from male-range doses |
| Bone density | Not established as an indication for testosterone | Estradiol is the hormone with the bone evidence. Ask about that and a DXA instead |
Two entries in that table deserve emphasis because clinics lean on them hardest. Fatigue is far more often thyroid disease, iron deficiency, sleep apnoea or depression, all of which a perimenopause biomarker panel can screen for. And bone density belongs to estradiol, which has the fracture evidence testosterone does not.
Doses, products and the regulatory reality
There is no testosterone product approved by the FDA for use in women. Every US prescription is therefore either a male product used off-label at a small fraction of its labelled dose, or a compounded preparation made by a pharmacy, which is not FDA-approved either.
The rest of the world differs. In the UK there is no licensed female product, so clinicians use a male gel off-label, and the NICE menopause guideline and the British Menopause Society both address that use. Australia is the exception: a 1% testosterone cream formulated at a female dose, AndroFeme 1 from Lawley Pharmaceuticals, is registered there for post-menopausal low sexual desire.
The female physiological dose is roughly one tenth of a male dose. This is the source of most dosing errors, and the errors run in one direction. A male gel sachet or pump actuation divided by eye is easy to over-deliver, and a small absolute error at this scale is a large proportional one. Ask for the dose in milligrams per day, not in pumps.
Route matters too. Transdermal gels and creams are preferred because they deliver a steady low dose and skip the first pass through the liver. Oral testosterone lowers HDL cholesterol and is not recommended for women. Injections are hard to dose at female levels because the smallest practical volume already overshoots.
Why supra-physiological dosing is the actual risk
Almost every serious side effect of testosterone in women follows from a blood level above the normal female range, not from testosterone itself. Keeping the level inside the range is the whole safety strategy.
Pellets are where this most often breaks. An implanted pellet releases a fixed dose for months, has been reported to produce levels well above the female physiological range, and cannot be turned down if a problem appears. Removing one is a minor surgical procedure. A gel can be halved tomorrow morning; a pellet cannot. Injections vs cream vs pellets covers the delivery-route mechanics in more depth.
The consequence is specific rather than vague. Voice deepening and clitoral enlargement are the two effects that may not reverse, and both are strongly associated with levels above the female range. A woman who accepts a pellet because it is convenient is accepting months of exposure she cannot modify.
Side effects, split by whether they reverse
The useful way to read the side-effect list is not by frequency but by reversibility. Listed from reversible to potentially permanent.
| Effect | Dose-dependent? | Reversible? | What to do |
|---|---|---|---|
| Acne and oily skin | Yes | Yes, usually within weeks of lowering or stopping | Reduce the dose and recheck the level. Do not push through it |
| Fluid retention and mild weight change | Yes | Yes | Reduce the dose |
| Mild increase in fine facial or body hair | Yes | Usually, slowly, once the dose comes down | Reduce the dose. Hair already grown may still need separate removal |
| Scalp hair thinning at the temples or crown | Yes | Partly. Established pattern loss may not fully recover | Act early rather than waiting to see if it settles |
| Lower HDL cholesterol | Mainly with oral testosterone | Yes, on stopping the oral route | Avoid oral testosterone. Use a transdermal product |
| Voice deepening or persistent hoarseness | Occurs mainly above the female range | No. Vocal cord changes are treated as permanent | Stop and contact the prescriber the same week |
| Clitoral enlargement | Occurs mainly above the female range | Often not | Stop and contact the prescriber the same week |
| Male-pattern hair growth on the face and chest | Occurs mainly above the female range | Often not fully | Stop and contact the prescriber the same week |
One practical rule follows. Treat acne and oily skin as information rather than as a nuisance to tolerate: they usually signal that the dose is at or above the top of your range, and they show up before the effects that do not reverse. A woman who reduces her dose when her skin changes rarely reaches the voice.
Testing and monitoring
Measure total testosterone before starting and again within roughly six weeks of a new or changed dose. The purpose of the follow-up test is not to prove the treatment is working, which symptoms answer, but to confirm the level has not gone above the female range.
Assay quality is a real problem here. Many laboratories run immunoassays calibrated for male concentrations, and these are imprecise at the low values normal in women, roughly 15 to 70 ng/dL for total testosterone. A method based on mass spectrometry is more reliable at female levels, and it is worth asking which one your lab uses before drawing conclusions from a borderline result.
SHBG changes how a total testosterone number should be read, because it binds most circulating testosterone and only the unbound fraction is active. Here is the exception that catches people out: oral estrogen raises SHBG substantially, and so does a combined oral contraceptive. A woman on oral estradiol can show a normal total testosterone and a low free testosterone, and switching her from oral to transdermal estradiol lowers SHBG and raises her free testosterone without any testosterone prescription at all. Check the route of her estrogen before concluding she needs androgen therapy.
Who should not take it
Testosterone is not appropriate for women who are pregnant, trying to conceive, or breastfeeding, because androgen exposure can virilise a female fetus. It is also avoided in untreated androgen-sensitive conditions and in active liver disease.
Caution applies with a personal history of hormone-sensitive breast cancer, since the long-term breast safety data do not exist. Significant existing acne, hirsutism or androgenic hair loss are relative reasons to avoid it, because testosterone will make each worse. Polycystic ovary syndrome, where androgens are already elevated, is not a setting for adding more.
See a physician promptly if your voice changes or becomes hoarse, if you notice clitoral enlargement, if new facial hair appears in a male pattern, or if you develop any unscheduled vaginal bleeding while on hormone therapy. These are not adjustments to make at the next annual review.
Where testosterone sits next to estrogen and progesterone
Testosterone is an adjunct to menopausal hormone therapy, not a substitute for it. Estradiol treats hot flashes, night sweats, vaginal dryness and bone loss. Progesterone or a progestogen protects the uterine lining in a woman who has a uterus. Testosterone does none of those things.
The practical sequence is to get estrogen and progestogen right first, wait long enough to judge the result, and only then consider whether low desire persists as a separate problem. Adding a third hormone into an unsettled regimen makes it impossible to tell which one caused what. HRT side effects and risks covers the estrogen and progestogen side of that decision, and HRT vs BHRT covers the compounded-versus-approved question that shapes which testosterone product you are likely to be offered.
For choosing where to have that conversation, compare the routes to a prescriber on doctor-led options rather than on which clinic markets testosterone hardest. The question that separates good prescribing from bad is narrow: does this provider treat post-menopausal low desire as the indication, dose in milligrams per day, and check a level at six weeks.
Frequently Asked Questions
What does testosterone replacement therapy do for women?
In post-menopausal women with hypoactive sexual desire disorder, it increases sexual desire, arousal, orgasm and sexual pleasure, and reduces the distress attached to low desire. That is the effect a global consensus position statement supports, and it is a moderate effect rather than a transformation. Everything else commonly attached to it, including energy, mood, focus, muscle and bone, is not an established indication. Those claims are not proven false, they are unproven, which is a different thing and a poor basis for a prescription.
Is testosterone replacement therapy safe for women?
At doses that keep blood levels inside the normal female range, short-term safety looks reassuring, with acne, oily skin and mild hair changes as the usual complaints. Two caveats matter. Long-term safety data beyond roughly two years of use are thin, so effects on the breast and on cardiovascular risk over a decade are not settled. And safety depends entirely on the dose: levels pushed above the female range carry the risk of voice deepening, clitoral enlargement and male-pattern hair growth, which may not reverse when the treatment stops.
What are the side effects of testosterone replacement therapy in women?
They split into two groups, and the split matters more than the list. Dose-dependent and reversible: acne, oily skin, fluid retention, mild extra facial or body hair, and scalp hair thinning if it is caught early. Potentially irreversible, and almost always the result of levels above the normal female range: voice deepening, clitoral enlargement and male-pattern beard or chest hair. Any change in your voice or clitoral size is a reason to stop and contact your prescriber that week, not at the next scheduled review.
Can you use testosterone replacement therapy for perimenopause?
It is prescribed to perimenopausal women, but the consensus evidence base sits in post-menopausal women, so this use is less well supported. Testosterone also does not fall sharply at perimenopause the way estrogen does, which weakens the replacement logic in this group. Perimenopausal low desire more often tracks back to sleep disruption, vaginal dryness, relationship factors, antidepressants or untreated vasomotor symptoms. Address those first, and get estradiol and progesterone right before adding a third hormone.
How does testosterone gel for women work, and what dose is used?
A transdermal gel or cream is rubbed into the skin daily, absorbed through it, and delivers a steady low dose without a first pass through the liver. The female dose is roughly a tenth of a male dose. In practice that means a fraction of a male sachet or a small measured amount of a female-formulated cream, applied to the lower abdomen or upper thigh rather than the shoulders. Wash your hands afterwards and cover the site, because testosterone transfers to a partner or child through skin contact.
Where can I find testosterone therapy for women near me?
A menopause specialist, a gynaecologist with a menopause interest, or an endocrinologist is the right starting point, and many general practitioners will refer rather than prescribe because the use is off-label. Telehealth hormone platforms also offer it, and the question to ask any provider is the same one: what dose, which product, and how will you confirm my level stays in the female range. Screen for pellet-first prescribing and for clinics that treat fatigue or brain fog as the indication. Our doctor-led options page compares the routes to a prescriber without crowning one.
How long does testosterone take to work in women, and when should you stop?
Allow roughly three months at a stable dose before judging it. Sexual response changes gradually, so a two-week verdict is meaningless. If there is no meaningful improvement in desire by six months at a correct female-range level, the standard advice is to stop rather than to increase the dose, because raising the dose above the female range trades an unproven benefit for a risk of permanent effects. Stopping is straightforward with a gel or cream and considerably harder with a pellet already implanted.
Does testosterone help with hot flashes or night sweats?
No. Vasomotor symptoms respond to estradiol, and testosterone is not a treatment for them. It is also not a treatment for vaginal dryness or painful sex, which respond to local vaginal estrogen at very low doses. Testosterone sits alongside estrogen and progesterone therapy as an adjunct for one specific problem, and it does not substitute for either. If hot flashes are the main complaint, the conversation is about estradiol, not testosterone.
Related
- HRT side effects and risks: the estrogen and progestogen side of the decision
- HRT vs BHRT: compounded versus approved products
- Perimenopause biomarker panel: what to test before any hormone decision
- Women's health: the full hub
- Doctor-led options: routes to a prescriber, compared on one rubric